Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06440980
PHASE1

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Official title: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

533

Start Date

2024-06-24

Completion Date

2025-06-02

Last Updated

2026-07-17

Healthy Volunteers

Yes

Interventions

DRUG

Orforglipron

Administered orally

Locations (7)

Anaheim Clinical Trials, LLC

Anaheim, California, United States

Collaborative Neuroscience Research, LLC

Los Alamitos, California, United States

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Altasciences Company Inc.

Overland Park, Kansas, United States

QPS

Springfield, Missouri, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Fortrea Clinical Research Unit

Madison, Wisconsin, United States